NeuroBo Pharmaceuticals completes enrollment in Phase 1 trial of DA-1726

NeuroBo Pharmaceuticals completed enrollment of the single ascending dose Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, for the treatment of obesity. A total of 45 participants have been enrolled. Data presented at the American Diabetes Association 84th Scientific Sessions showed that DA-1726 demonstrated superior weight loss compared to survodutide, a drug with the same mechanism of action, while also demonstrating retention of relative lean body mass preservation compared to survodutide while also exhibiting superior glucose lowering. NeuroBo expects to report top-line data from the SAD Part 1 portion of the Phase 1 clinical trial in Q3 of this year and top-line data from the MAD Part 2 in Q1 2025. Further, upon clearance of an updated Investigational New Drug application with the FDA, expects to dose the first patient in the planned Part 3 of the trial during Q3 2025, providing an interim data readout in or around mid-2026 and issuing top-line results in the second half of 2026. Part 2, currently enrolling subjects, is designed as a MAD study, and is expected to enroll approximately 36 participants. The primary endpoint of the Phase 1 trial will assess the safety and tolerability of DA-1726.